|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A21950401]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2002.05.11)(ÇöÀç¾à°¡)
\9 ¿ø/1Á¤(2002.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
°íÃÊ¿(²É°¡·ç ¾Ë·¹¸£±âºñ¿°(ÄÚ¿°)), µÎµå·¯±â, °¡·Á¿ò¼º ÇǺÎÁúȯ(½ÀÁø․ÇǺο°, ÇǺΰ¡·Á¿òÁõ, ¾à¹°¹ßÁø), ¾Ë·¹¸£±â ºñ¿°, Ç÷°ü¿îµ¿¼º ÄÚ¿°, ÄÚ°¨±â¿¡ ÀÇÇÑ Àçä±â¡¤Ä๰¡¤±âħ, Ç÷°ü¿îµ¿¼º ºÎ±â
|
| 1ÀÏ ÃÖ´ë Åõ¿©·® |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : Ŭ·Î¸£Æä´Ï¶ó¹Î¸»·¹»ê¿°À¸·Î¼ 1ȸ 2 〜 6 mg 1ÀÏ 2 〜 4ȸ °æ±¸Åõ¿©ÇÑ´Ù.
1ÀÏ 24 mgÀ» ÃʰúÇØ¼´Â ¾ÈµÈ´Ù.
|
| °æ°í |
ÀÌ ¾àÀ» º¹¿ë(»ç¿ë)ÇÏ´Â µ¿¾È ´ÙÀ½ÀÇ ÇàÀ§¸¦ ÇÏÁö ¸» °Í.
Á¹À½À» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀ» Åõ¿©ÁßÀΠȯÀÚ´Â ÀÚµ¿Â÷ ¿îÀü µî À§ÇèÇÑ ±â°èÁ¶ÀÛÀ» ÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à ¶Ç´Â À¯»ç ÈÇÕ¹°¿¡ °ú¹Î¹ÝÀÀ º´·ÂÀÌ Àִ ȯÀÚ
2) ³ì³»Àå ȯÀÚ(Ç×Äݸ° ÀÛ¿ë¿¡ ÀÇÇØ ¾È¾ÐÀÌ »ó½ÂµÇ¾î ³ì³»ÀåÀÌ ¾Ç鵃 ¼ö ÀÖ´Ù)
3) Àü¸³¼±ºñ´ë µî ÇϺοä·ÎÆó»ö¼º Áúȯ ȯÀÚ
4) ¹Ì¼÷¾Æ ¹× ½Å»ý¾Æ
5) MAO ¾ïÁ¦Á¦ Åõ¿©ÁßÀΠȯÀÚ
|
| ½ÅÁßÅõ¿© |
1) 3¼¼ ¹Ì¸¸ À¯¾Æ
2) ÀӺΠ¹× ¼öÀ¯ºÎ
3) °í·ÉÀÚ
4) ¾È³»¾Ð»ó½Â ȯÀÚ
5) °©»ó»ù±â´ÉÇ×Áø ȯÀÚ
6) ÇùÂø¼º¼Òȼº±Ë¾ç ¶Ç´Â À¯¹®½ÊÀÌÁöÀå Æó»ö ȯÀÚ
7) ¼øÈ¯°èÁúȯ ȯÀÚ
8) °íÇ÷¾Ð µî ½ÉÇ÷°ü°è Áúȯ ȯÀÚ
9) ±â°üÁö¿°, ±â°üÁöÈ®ÀåÁõ ¹× õ½ÄȯÀÚ
10) °£Áú ȯÀÚ
11) °£Áúȯ ȯÀÚ
12) ³úÁ¹Áß º´·ÂÀÌ Àִ ȯÀÚ
13) ÁßÁõ °ü»óµ¿¸ÆºÎÀü ȯÀÚ
14) ¹ßÀÛ º´·ÂÀ» °¡Áø ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
´ÙÀ½°ú °°Àº °æ¿ì ÀÌ ¾àÀÇ º¹¿ëÀ» Áï°¢ ÁßÁöÇϰí ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í. »ó´ã½Ã °¡´ÉÇÑÇÑ ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í.
1) û»öÁõ, È£Èí°ï¶õ, ÈäºÎºÒÄè°¨, Ç÷¾ÐÀúÇÏ µîÀÇ ¼îÅ© Çö»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
2) °æ·Ã, Âø¶õ µîÀÇ ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
3) Àç»ýºÒ·®¼ººóÇ÷, ¹«°ú¸³±¸Áõ µîÀÇ ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
4) ¹ßÁø, ÇÞºû ³ëÃâ½Ã ÇǺΠ°ú¹Î¹ÝÀÀ, ¹Ú¸®¼º ÇǺο°, µÎµå·¯±â, ¿¬Ãà, ±ÙÇã¾à, ÇùÁ¶ºÒ´É µîÀÇ °ú¹Î¹ÝÀÀÀÌ ³ªÅ¸³ª´Â °æ¿ì
5) ÁøÁ¤, Á¹À½, ½Å°æ°ú¹Î, µÎÅë, ÃÊÁ¶°¨, º¹½Ã, ºÒ¸é, ¾îÁö·³, À̸í, ÀüÁ¤Àå¾Ö, ´ÙÇàÁõ, Á¤¼ºÒ¾È, È÷½ºÅ׸®, ÁøÀü, ½Å°æ¿°, ÇùÁ¶ÀÌ»ó, °¨°¢ÀÌ»ó, ¹«½Ã, ÁýÁ߷°¨¼Ò, ±Çۨ µîÀÇ Á¤½Å½Å°æ°è ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
6) ±¸°¥, °¡½¿¾²¸², ½Ä¿åºÎÁø, ¼ÒȺҷ®, ±¸¿ª, ±¸Åä, º¹Åë, º¯ºñ, ¼³»ç µîÀÇ ¼Òȱâ°è ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
7) ºó´¢, ¹è´¢°ï¶õ, ¿äÆó, ¿äÀú·ù µîÀÇ ºñ´¢±â°è ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
8) ÀúÇ÷¾Ð, ½É°èÇ×Áø, ºó¸Æ, ºÎÁ¤¸Æ, ±â¿Ü¼öÃà, °£¿°, Ȳ´Þ, ¹Ì¾à¸Æ(ÁÖ»çÁ¦¿¡ ÇÑÇÔ) µîÀÇ ¼øÈ¯±â°è ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
9) ÄÚ ¶Ç´Â ±âµµÀÇ °ÇÁ¶, ±â°üºÐºñ¾×ÀÇ Á¡¼ºÈ, õ¸í, ÄÚ¸·Èû µîÀÇ È£Èí±â°è ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
10) ¿ëÇ÷¼ººóÇ÷, Ç÷¼ÒÆÇ°¨¼Ò µîÀÇ Ç÷¾× ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
11) °£±â´É Àå¾Ö°¡ ³ªÅ¸³ª´Â °æ¿ì
12) ÁÖ»çºÎÀ§¿¡ ÀϽÃÀûÀÎ ÀÚ±Ø, ÀÛ¿°¨ÀÌ ³ªÅ¸³ª´Â °æ¿ì(ÁÖ»çÁ¦¿¡ ÇÑÇÔ)
13) ¿ÀÇÑ, ¹ßÇÑÀÌ»ó, ÈäÅë, ÇǷΰ¨, ¿ù°æÀÌ»ó µîÀÇ ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì
|
| ÀϹÝÀû ÁÖÀÇ |
1) ¾ËÄÚ¿Ã, ÁßÃ߽Űæ¾ïÁ¦Á¦ º´¿ë(ÇÔ²² º¹¿ë) ½Ã Á¹À½À» À¯¹ßÇÒ ¼ö ÀÖ´Ù.
2) Ŭ·Î¸£Æä´Ï¶ó¹ÎÀº Æä´ÏÅäÀδë»ç¸¦ ¾ïÁ¦ÇÏ¿© Æä´ÏÅäÀÎ µ¶¼ºÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù.
3) Ŭ·Î¸£Æä´Ï¶ó¹ÎÀÇ Ä¡»ç·®Àº üÁß kg´ç 25 ¡ 50 mgÀÌ´Ù. Áõ»óÀ¸·Î´Â ÁøÁ¤, ÁßÃ߽Űæ°è ºñÁ¤»óÀû ÀÚ±Ø, Áßµ¶¼º Á¤½Åº´, °æ·Ã, ¹«È£Èí, Á¤½ÅÂø¶õ, Ç×Äݸ° È¿°ú, ½ÇÁ¶Áõ, ºÎÁ¤¸ÆÀ» ºñ·ÔÇÑ ½ÉÇ÷°ü°è ÇãÅ»Áõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç À̶§¿¡´Â Åä±Ù½Ã·´À» ÀÌ¿ëÇØ ±¸Å並 À¯¹ß½ÃŰ°Å³ª À§¼¼Ã´À» ÇÑ´Ù.
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
1) ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÒ °Í.
2) ÀǾàǰÀ» ¿ø·¡ ¿ë±â¿¡¼ ²¨³»¾î ´Ù¸¥ ¿ë±â¿¡ º¸°üÇÏ´Â °ÍÀº ÀǾàǰ ¿À¿ë(À߸ø »ç¿ë)¿¡ µû¸¥ »ç°í ¹ß»ýÀ̳ª ÀǾàǰ ǰÁú ÀúÇÏÀÇ ¿øÀÎÀÌ µÉ ¼ö ÀÖÀ¸¹Ç·Î ¿ø·¡ÀÇ ¿ë±â¿¡ ³Ö°í ²À ´Ý¾Æ º¸°üÇÒ °Í.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Chlorpheniramine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Chlorpheniramine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
|
| Pharmacology |
Chlorpheniramine¿¡ ´ëÇÑ Pharmacology Á¤º¸ In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Chlorpheniramine, is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
|
| Metabolism |
Chlorpheniramine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)Cytochrome P450 2D6 (CYP2D6)
|
| Protein Binding |
Chlorpheniramine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 72%
|
| Half-life |
Chlorpheniramine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 21-27 hours
|
| Absorption |
Chlorpheniramine¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed in the gastrointestinal tract.
|
| Biotransformation |
Chlorpheniramine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Primarily hepatic via Cytochrome P450 (CYP450) enzymes.
|
| Toxicity |
Chlorpheniramine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 = 306 mg/kg in humans, mild reproductive toxin to women of childbearing age.
|
| Drug Interactions |
Chlorpheniramine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Donepezil Possible antagonism of actionGalantamine Possible antagonism of actionRivastigmine Possible antagonism of actionEthotoin The antihistamine increases the effect of hydantoinFosphenytoin The antihistamine increases the effect of hydantoinMephenytoin The antihistamine increases the effect of hydantoinPhenytoin The antihistamine increases the effect of hydantoin
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Chlorpheniramine¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2D6
Beta Blockers:
S-metoprolol
propafenone
timolol
Antidepressants:
amitriptyline
clomipramine
desipramine
imipramine
paroxetine
Antipsychotics:
haloperidol
risperidone
thioridazine
aripiprazole
codeine
dextromethorphan
duloxetine
flecainide
mexiletine
ondansetron
tamoxifen
tramadol
venlafaxine
INHIBITORS
CYP 2D6
amiodarone
buproprion
**chlorpheniramine**
cimetidine
clomipramine
duloxetine
fluoxetine
haloperidol
methadone
mibefradil
paroxetine
quinidine
ritonavir
INDUCERS
CYP 2D6
N/A
|
| Food Interaction |
Chlorpheniramine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food.Avoid alcohol.
|
| Drug Target |
[Drug Target]
|
| Description |
Chlorpheniramine¿¡ ´ëÇÑ Description Á¤º¸ A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]
|
| Dosage Form |
Chlorpheniramine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Syrup OralTablet OralTablet, extended release Oral
|
| Drug Category |
Chlorpheniramine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Allergic AgentsAntihistaminesAntipruriticsHistamine H1 Antagonists
|
| Smiles String Canonical |
Chlorpheniramine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
|
| Smiles String Isomeric |
Chlorpheniramine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CC[C@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
|
| InChI Identifier |
Chlorpheniramine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
|
| Chemical IUPAC Name |
Chlorpheniramine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
|
| Drug-Induced Toxicity Related Proteins |
MALEATE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Intercellular adhesion molecule 1 Drug:maleate Toxicity:hepatic injury. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2020-08-07
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|